-
05:30:27 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

BMY Stock News

06/24/22 7:05 PM
NYSE : BMY
fda approval
U.S. FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
Bristol Myers Squibb today announced that the U.S. Food and Drug Administration has approved Breyanzi ®, a CD19-directed chimeric antigen receptor T cell therapy, for the treatment of adult patients with large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell...
RHEA-AI
very positive
06/24/22 12:52 PM
NYSE : BMY
Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
Bristol Myers Squibb today announced new post-hoc analyses from the Zeposia Phase 3 DAYBREAK open-label extension and Phase 3 SUNBEAM trials, showing early Zeposia use demonstrated cognitive benefits in people with relapsing multiple sclerosis, with the greatest effect seen in people with high thalamic volume, supporting an association between...
RHEA-AI
positive
06/24/22 12:51 PM
NYSE : BMY
covid-19
New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia (ozanimod)
Bristol Myers Squibb today announced new data on COVID-19 vaccine responses in participants treated with Zeposia from the ongoing Phase 3 DAYBREAK open-label extension study in relapsing multiple sclerosis. “We are committed to partnering with the research and medical communities to understand how our medicines should best be used in the context of the...
RHEA-AI
neutral
06/20/22 6:59 AM
NYSE : BMY
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy
Bristol Myers Squibb today announced that the European Medicines Agency has validated its type II variation application for extension of the indication for Breyanzi to treat adult patients with diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3 B, who are refractory or...
RHEA-AI
neutral
06/15/22 4:16 PM
NYSE : BMY
management
Bristol Myers Squibb Elects Deepak L. Bhatt, M.D., M.P.H. to Board of Directors
Bristol Myers Squibb today announced that its Board of Directors has elected Deepak L. Bhatt, M.D., MPH., to the Board, effective June 14, 2022. Dr. Bhatt will serve as a member of the Science& Technology Committee of the Board of Directors. Deepak L. Bhatt to our Board of Directors,” said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb.“...
RHEA-AI
positive
06/07/22 6:59 AM
NYSE : BMY
conferences
Bristol Myers Squibb to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
Bristol Myers Squibb today announced that the company will take part in a fireside chat at Goldman Sachs’ 43 rd Annual Global Healthcare Conference in Rancho Palos Verdes, California on Wednesday, June 15, 2022. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help...
RHEA-AI
neutral
06/06/22 6:59 AM
NYSE : BMY
clinical trial
Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
Bristol Myers Squibb today announced five-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of first-line treatment with Opdivo plus Yervoy compared to chemotherapy in patients with metastatic non-small cell lung cancer, regardless of PD-L1 expression levels.
RHEA-AI
neutral
06/06/22 6:59 AM
NYSE : BMY
clinical trial
Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer
Bristol Myers Squibb today announced three-year follow-up results from the Phase 3 CheckMate -9 LA trial demonstrating durable survival benefits with Opdivo plus Yervoy with two cycles of chemotherapy compared to four cycles of chemotherapy in previously untreated patients with metastatic non-small cell lung cancer. These data will be featured in a...
RHEA-AI
positive